Preparation method of full-spectrum polypeptide compound

Abstract

The invention relates to the technical field of skin care products, in particular to a preparation method of a full-spectrum polypeptide complex, water-soluble polypeptide and a carrier material are mixed, a polysaccharide microsphere wrapping technology is adopted to prepare water-soluble polypeptide microspheres, and the polysaccharide microspheres are used for isolating degradation of skin surface protease on the water-soluble polypeptide; lipid-soluble polypeptide and a carrier material are mixed, a phospholipid liposome wrapping technology is adopted to prepare the lipid-soluble polypeptide liposome, the structure of the phospholipid liposome is similar to that of skin cuticle lipid, and the phospholipid liposome is used for promoting the lipid-soluble polypeptide to penetrate through the cuticle. The invention constructs a full-spectrum polypeptide system. The water-soluble polypeptide can quickly permeate into the superficial layer of the skin to play the roles of moisturizing, relieving and repairing in time and relieving the dryness and sensitivity of the skin; the fat-soluble polypeptide penetrates through the cuticle by means of a special delivery carrier, acts on the corium layer, and accurately targets a synthetic pathway of fibroblasts and collagen, so that deep wrinkle resistance and skin tightening are realized.

Description

Technical Field

[0001] This invention relates to the field of skincare technology, specifically a method for preparing a full-spectrum polypeptide complex. Background Technology

[0002] In the field of skincare and skin repair, peptides have become one of the core active ingredients due to their good compatibility with skin physiology, low irritation, and well-defined activity. However, existing peptide products still face multi-dimensional technical bottlenecks in both research and development and practical application, making it difficult to meet the industry's demand for highly effective, stable, and safe products.

[0003] First, peptide formulation systems have limitations. Existing technologies mostly focus on developing single soluble or single-functional peptides, failing to form a comprehensive system. The skin structure has layered characteristics: the stratum corneum of the epidermis is a lipid-soluble environment, while the dermis is a water-soluble environment. A single soluble peptide can only act on a specific layer, failing to achieve full-spectrum efficacy coverage. Furthermore, different peptides have single functions and lack multi-target synergistic mechanisms, resulting in fragmented core efficacy such as anti-wrinkle and repair effects, making it difficult to form a complete efficacy chain. Second, peptide delivery efficiency is low. Peptide molecules are easily degraded by proteases on the skin surface, and the stratum corneum forms a natural barrier for large peptide molecules. Traditional technologies lack targeted delivery carriers, causing peptides to remain mostly on the skin surface and unable to effectively penetrate the dermis. Some technologies attempting to use carriers suffer from poor carrier-peptide compatibility, leading to carrier breakage and premature peptide release, further reducing bioavailability and resulting in a common phenomenon of effectiveness in in vitro experiments but ineffectiveness in human applications.

[0004] Furthermore, there is an imbalance between the stability and safety of the formulation system. Existing formulations often focus on the simple dissolution of active ingredients, neglecting the overall balance of the system. Peptides are prone to aggregation or degradation due to pH fluctuations and temperature changes, leading to product layering, discoloration, and activity reduction. Some technologies use high concentrations of irritating preservatives to ensure stability, or choose base solvents with poor compatibility with peptides, which can easily cause skin allergies, weaken peptide activity, and have poor adaptability to special skin types. Finally, the efficacy evaluation system is disconnected from practical application. Existing evaluations are mostly limited to in vitro cell experiments, lacking a complete in vitro and in vivo chain. Some products are effective in vitro, but their efficacy is difficult to sustain in vivo. Moreover, the evaluation indicators are singular, neglecting key dimensions such as skin elasticity improvement and barrier repair, leading to an overestimation of the product's actual application value and failing to meet consumers' comprehensive skin improvement needs. Summary of the Invention

[0005] The purpose of this invention is to address the shortcomings of existing technologies by proposing a method for preparing a full-spectrum polypeptide complex.

[0006] A method for preparing a full-spectrum polypeptide complex includes the following steps: (1) Preparation of water-soluble polypeptide microspheres: Water-soluble polypeptides are mixed with carrier materials and water-soluble polypeptide microspheres are prepared by polysaccharide microsphere encapsulation technology. The polysaccharide microspheres are used to isolate the degradation of water-soluble polypeptides by proteases on the skin surface. (2) Preparation of lipid-soluble polypeptide liposomes: lipid-soluble polypeptides are mixed with carrier materials and lipid-soluble polypeptide liposomes are prepared by phospholipid liposome encapsulation technology. The structure of the phospholipid liposomes is similar to that of the lipids in the stratum corneum of the skin, which is used to promote the penetration of lipid-soluble polypeptides into the stratum corneum. (3) Complex mixing: The water-soluble polypeptide microspheres obtained in step (1) are mixed with the lipid-soluble polypeptide liposomes obtained in step (2), and stirred at 50°C to 58°C for 45 to 50 minutes to obtain a full-spectrum polypeptide complex intermediate. The full-spectrum polypeptide complex intermediate is composed of water-soluble polypeptides and lipid-soluble polypeptides, which act on the superficial layer of the skin and the dermis, respectively. (4) Formulation system construction: Add a basic solvent to the full-spectrum polypeptide complex intermediate, then add a composite preservative, and stir evenly; the basic solvent is a combination of butanediol and glycerol, with the butanediol addition ratio being 20% ​​to 25% and the glycerol addition ratio being 10% to 12%; the composite preservative is a combination of 1,2-hexanediol and pentanediol, with the 1,2-hexanediol addition ratio being 0.5% to 0.8% and the pentanediol addition ratio being 0.5% to 0.8%; (5) Finished product adjustment: Adjust the pH of the system to 5.0 to 6.0 with acid or alkali, add purified water, and prepare a full-spectrum polypeptide complex product with a concentration of 10% to 15%. The finished product is used for skin anti-wrinkle and repair.

[0007] Preferably, the water-soluble polypeptide includes at least one of acetyl hexapeptide-8, acetyl octapeptide-3, acetyl hexapeptide-1, acetyl tetrapeptide-9, palmitoyl tetrapeptide-7, acetyl tetrapeptide-2, and tripeptide-1, used to construct the water-soluble component in the full-spectrum polypeptide system.

[0008] Preferably, the lipid-soluble polypeptide includes at least one of palmitoyl pentapeptide-4, hexapeptide-11, snake venom-like peptide, palmitoyl tripeptide-1, and palmitoyl tripeptide-5, used to construct the lipid-soluble component in the full-spectrum polypeptide system.

[0009] Preferably, in step (1), the carrier material of the water-soluble polypeptide microspheres is one of polyethylene glycol, polyvinylpyrrolidone, and polyvinyl alcohol, and the carrier material is adapted to the water-soluble polypeptide to achieve slow release; in step (2), the carrier material of the lipid-soluble polypeptide liposomes is one of polyethylene glycol octyl ether, polyglycerol ester, and polyvinyl alcohol octyl ester, and the carrier material is adapted to the lipid-soluble polypeptide to improve the stratum corneum penetration efficiency.

[0010] Preferably, the acid used to adjust the pH value in step (5) is hydrochloric acid, and the base used is sodium hydroxide.

[0011] Preferably, the mass ratio of water-soluble peptide to carrier material in step (1) is 1:(5-10).

[0012] Preferably, in step (2), the mass ratio of the lipid-soluble polypeptide to the carrier material is 1:(5-10).

[0013] Preferably, in step (3), the mixing mass ratio of water-soluble polypeptide microspheres to lipid-soluble polypeptide liposomes is (1-2):1.

[0014] Preferably, the stirring rate in step (4) is 200 rpm to 300 rpm and the stirring time is 20 minutes to 30 minutes.

[0015] A full-spectrum polypeptide complex is prepared using the method described above. The complex comprises a dual-targeting structure of water-soluble polypeptide microspheres and lipid-soluble polypeptide liposomes, and the full-spectrum polypeptides cover both water-soluble and lipid-soluble types.

[0016] Compared with the prior art, the beneficial effects of the present invention are: 1. This invention overcomes the limitations of single peptides by scientifically combining multiple water-soluble and fat-soluble peptides to construct a full-spectrum peptide system. Water-soluble peptides can quickly penetrate the superficial layers of the skin, providing immediate moisturizing, soothing, and repairing effects, relieving dryness and sensitivity. Fat-soluble peptides, aided by a dedicated delivery carrier, penetrate the stratum corneum and act on the dermis, precisely targeting fibroblasts and collagen synthesis pathways to achieve deep anti-wrinkle and skin firming. The two types of peptides complement each other functionally, providing superficial repair and deep anti-wrinkle effects, covering the epidermis to the dermis. This addresses the problems of fragmented efficacy and limited scope of action in existing products, meeting the dual needs of immediate skin soothing and long-term anti-wrinkle care.

[0017] 2. This invention addresses the characteristics of two types of peptides by employing polysaccharide microsphere encapsulation and phospholipid liposome encapsulation technologies to construct a dual-target delivery system. The polysaccharide microspheres isolate water-soluble peptides from protease degradation and provide slow release, prolonging the duration of action. The phospholipid liposomes, with a structure similar to stratum corneum lipids, rapidly penetrate the barrier through fusion and permeation mechanisms, reducing peptide permeation loss and efficiently delivering them to the dermal target. This system significantly improves peptide permeability and activity retention, avoiding wasted efficacy and resolving the core contradiction of high in vitro activity but poor in vivo efficacy.

[0018] 3. This invention achieves three goals—active stability, safety and gentleness, and skin compatibility—through optimized formulation. The base solvent combines dissolving and moisturizing properties, ensuring uniform dispersion of peptides and long-lasting skin hydration. The composite preservative matrix uses a blend of low-irritant preservatives to ensure long-term product stability, reduce the risk of skin irritation, and suitability for sensitive skin. Precise pH adjustment matches the skin's physiological pH, reducing barrier stress responses and enhancing gentleness. This addresses the problems of poor stability, high irritation, and low skin compatibility in existing products, extending shelf life and improving the user experience. 4. This invention constructs a complete evaluation chain, including in vitro cell experiments, in vitro skin penetration experiments, and long-term human efficacy experiments. From the molecular level of cell proliferation and collagen synthesis to the level of skin penetration efficiency, and then to the practical application level of wrinkle improvement and skin elasticity enhancement, it verifies product efficacy from multiple dimensions. Furthermore, the evaluation indicators cover key dimensions such as wrinkle reduction and skin elasticity improvement, ensuring stable efficacy in practical applications, avoiding overestimation of efficacy, truly meeting consumers' comprehensive skin improvement needs, and providing reliable technical support for the product's market application. Attached Figure Description

[0019] Figure 1 This is a schematic diagram illustrating the fibroblast proliferation rate in this invention; Figure 2 This is a schematic diagram of gene expression levels in this invention; Figure 3 This is a graph showing the test results of the average elastic R2 value in this invention; Figure 4 This is a trend chart showing the variation of the average area of ​​crow's feet wrinkles in this invention. Figure 5 This is a trend graph showing the variation of the average number of wrinkles in the test results of this invention; Figure 6 This is a schematic diagram of subject 003 in this invention; Figure 7 This is a schematic diagram of subject 012 in this invention; Figure 8 This is a schematic diagram of subject 025 in this invention; Figure 9 This is a schematic diagram of subject 003 in this invention. Detailed Implementation

[0020] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0021] Example 1: Preparation of water-soluble polypeptide microspheres: Acetyl hexapeptide-8 1.0%, acetyl octapeptide-3 1.0%, acetyl hexapeptide-1 1.0%, acetyl tetrapeptide-9 1.0%, palmitoyl tetrapeptide-7 1.0%, acetyl tetrapeptide-2 1.0%, and tripeptide-1 4.0% were mixed with polyethylene glycol, and water-soluble polypeptide microspheres were prepared by polysaccharide microsphere encapsulation technology. Preparation of lipid-soluble polypeptide liposomes: Palmitoyl pentapeptide-4 1.0%, hexapeptide-11 1.0%, snake venom-like peptide 1.0%, palmitoyl tripeptide-1 1.0%, and palmitoyl tripeptide-5 1.0% were respectively mixed with polyethylene glycol octyl ether, and lipid-soluble polypeptide liposomes were prepared by phospholipid liposome encapsulation technology; Complex mixing: The above water-soluble polypeptide microspheres were mixed with lipid-soluble polypeptide liposomes and stirred at 50°C for 45 minutes to obtain a full-spectrum polypeptide complex intermediate; Formulation system construction: Add 20% butylene glycol and 10% glycerol as base solvents, and add 0.5% 1,2-hexanediol and 0.5% pentanediol to form an anti-corrosion matrix, and stir evenly; Finished product preparation: Adjust the pH value to 5.5 with sodium hydroxide, add an appropriate amount of purified water, and prepare a 10% concentration of full-spectrum polypeptide complex.

[0022] Example 2: Preparation of water-soluble polypeptide microspheres: Acetyl hexapeptide-8 2.0%, acetyl octapeptide-3 2.0%, acetyl hexapeptide-1 2.0%, acetyl tetrapeptide-9 2.0%, palmitoyl tetrapeptide-7 2.0%, acetyl tetrapeptide-2 2.0%, and tripeptide-1 8.0% were mixed with polyvinylpyrrolidone, and water-soluble polypeptide microspheres were prepared by polysaccharide microsphere encapsulation technology. Preparation of lipid-soluble polypeptide liposomes: Palmitoyl pentapeptide-4 2.0%, hexapeptide-11 2.0%, snake venom-like peptide 2.0%, palmitoyl tripeptide-1 2.0%, and palmitoyl tripeptide-5 2.0% were mixed with polyglycerol esters respectively, and lipid-soluble polypeptide liposomes were prepared by phospholipid liposome encapsulation technology. Complex mixing: The above water-soluble polypeptide microspheres and lipid-soluble polypeptide liposomes were mixed and stirred at 55°C for 50 minutes to obtain a full-spectrum polypeptide complex intermediate; Formulation system construction: Add 25% butanediol and 12% glycerol as base solvents, and add 0.8% 1,2-hexanediol and 0.8% pentanediol to form an anti-corrosion matrix, and stir evenly; Finished product adjustment: Adjust the pH value to 6.0 with hydrochloric acid, add an appropriate amount of purified water, and prepare a 15% concentration of full-spectrum polypeptide complex.

[0023] Example 3: Preparation of water-soluble polypeptide microspheres: Acetyl hexapeptide-8 5.0%, acetyl octapeptide-3 5.0%, acetyl hexapeptide-1 5.0%, acetyl tetrapeptide-9 5.0%, palmitoyl tetrapeptide-7 5.0%, acetyl tetrapeptide-2 5.0%, and tripeptide-1 20.0% were respectively mixed with polyvinyl alcohol, and water-soluble polypeptide microspheres were prepared by polysaccharide microsphere encapsulation technology; Preparation of lipid-soluble polypeptide liposomes: Palmitoyl pentapeptide-4 5.0%, hexapeptide-11 5.0%, snake venom-like peptide 5.0%, palmitoyl tripeptide-1 5.0%, and palmitoyl tripeptide-5 5.0% were respectively mixed with polyvinyl octyl ester, and lipid-soluble polypeptide liposomes were prepared by phospholipid liposome encapsulation technology; Complex mixing: The above water-soluble polypeptide microspheres were mixed with lipid-soluble polypeptide liposomes and stirred at 58°C for 45 minutes to obtain a full-spectrum polypeptide complex intermediate; Formulation system construction: Add 22% butylene glycol and 11% glycerol as base solvents, and add 0.6% 1,2-hexanediol and 0.6% pentanediol to form an anti-corrosion matrix, and stir evenly; Finished product preparation: Adjust the pH value to 5.0 with sodium hydroxide, add an appropriate amount of purified water, and prepare a 12% concentration of full-spectrum polypeptide complex.

[0024] Example 4: Cell proliferation experiment is as follows: (1) Test sample: Experimental group: The polypeptide stock solutions prepared in Examples 1, 2 and 3 were diluted with DMEM medium to a final concentration of 50 μg / mL.

[0025] Positive control group: Culture medium containing 10 ng / mL basic fibroblast growth factor (bFGF).

[0026] Negative control group: Equal volume of blank DMEM medium (containing 0.1% DMSO solvent).

[0027] (2) Experimental methods Cell culture: Human skin fibroblasts (HSF) were selected and seeded in 96-well plates (density 5×10³ cells / well) and cultured at 37℃ and 5% CO2 for 24 hours until adherence.

[0028] CCK-8 assay for proliferation activity: Discard the original culture medium and add culture medium containing the same concentration of peptide to each well (6 replicates per group). After culturing for 24 hours, add 10 μL CCK-8 reagent to each well and incubate for 2 hours. Measure the absorbance (OD value) at 450 nm using a microplate reader and calculate the cell proliferation rate. Proliferation rate (%) = (OD value of experimental group - OD value of blank control group) / (OD value of negative control group - OD value of blank control group) × 100% The conclusions are as follows: The final test results are as follows Figure 1 The compound peptide stock solutions prepared in Examples 1, 2, and 3, with a final concentration of 50 μg / mL, all showed good proliferation effects on human fibroblasts, slightly lower than the positive control at the same concentration; the results indicate that the compound peptide stock solutions prepared by this method have good anti-wrinkle and skin repair effects. Example 5: In vitro anti-wrinkle efficacy test is as follows: (1) Collagen secretion detection: HSF cells were seeded in 6-well plates. The experimental groups were added with culture medium containing the polypeptide stock solutions prepared in Examples 1, 2, and 3 (final concentration 50 μg / mL), while the control group was added with an equal volume of blank culture medium. After 48 hours of culture, the content of type I collagen (COL1A1) in the cell supernatant was detected using an ELISA kit.

[0029] The final test results are as follows Figure 2 The results showed that Examples 1, 2, and 3 could significantly promote the production of type I collagen (COL1A1) and type III collagen (COL3A1) in fibroblasts, indicating that all three serums have good anti-wrinkle effects.

[0030] Example 6: Skin permeability test as follows: (1) Test samples and materials Polypeptide stock solution: Each contains 5% of the polypeptide stock solution prepared in Examples 1, 2 and 3, dissolved in phosphate buffer at pH 7.4.

[0031] Control group: Normally formulated polypeptide stock solution Skin model: Artificial skin model.

[0032] Receiving solution: PBS (containing 0.01% NaN3 to prevent microbial contamination) or physiological saline.

[0033] (2) Experimental setup and methods: Franz diffusion cell method (standard in vitro permeability test) Apparatus: Vertical Franz diffusion cell (effective diffusion area 1.77 cm²) 2 (Receiving chamber volume 7mL).

[0034] step: The skin / membrane was fixed between the donor chamber and the receiver chamber with the stratum corneum facing upwards; 1 mL of the polypeptide stock solution from different embodiments was added to the donor chamber (no penetration enhancer was added to the control group); the receiver chamber was magnetically stirred (600 rpm) and maintained at 32±1℃ (simulating body surface temperature); 200 μL of receiver solution was sampled at time points of 0.5, 1, 2, 4, 8, 12, and 24 hours (and isothermal fresh receiver solution was added at the same time).

[0035] Detection and Analysis: Quantitative detection: C18 column, mobile phase acetonitrile / water (containing 0.1% TFA), detection wavelength 220 nm, calculation of cumulative permeate (Q) n μg / cm 2 ).

[0036] The conclusion is as follows: The final test results are shown in Table 1 below. The composite polypeptide stock solutions prepared in Examples 1, 2 and 3 of this invention have better permeability than the control group, and their permeability is more than twice that of ordinary stock solutions.

[0037] Table 1: Example 7: Long-term comparative test of human efficacy Healthy female volunteers aged 30-60 (n=30) with noticeable facial wrinkles (such as crow's feet and nasolabial folds) were divided into an experimental group (using the 10% polypeptide stock solution prepared according to this invention) and a placebo group (a mixed solution of 20% butylene glycol, 10% glycerin, and 70% purified water). The testing period was 12 weeks (twice daily), with follow-up at baseline (week 0), 2 weeks, 4 weeks, 8 weeks, and 12 weeks. The wrinkle area was measured using VISIA.

[0038] The experimental test results are shown in Table 2 below: The results in Table 2 show that the stock solution prepared in the embodiments of the present invention has a good anti-wrinkle effect and can significantly reduce the area of ​​facial wrinkles.

[0039] Example 8: Human efficacy test of a single sample Experimental sample: 1% of the polypeptide complex stock solution prepared in Example 3.

[0040] Experimental Protocol: Recruit 30 healthy volunteers, aged 30-60, male or female; volunteers must have noticeable crow's feet and nasolabial folds around the eyes and forehead. Volunteers will apply the test sample twice daily, morning and evening, and the wrinkle condition will be assessed using VISIA on days 0, 14, and 28.

[0041] The test results are analyzed as follows: (1) Elasticity R2 Note: Significance marking method: “ns” indicates no statistical difference. p ≥0.05; "*" indicates a significant difference. p＜ 0.05; Change rate = (after use - before use) / before use * 100%.

[0042] Figure 3 The graph shows the results of the average R2 elasticity test. Compared with before product use, after 14 and 28 days of product use, the skin elasticity R2 showed a significant increase compared with the baseline value, increasing by 8.18% and 14.54% respectively, indicating that the product has anti-wrinkle effects.

[0043] (2) Area of ​​wrinkles at the corners of the eyes Note: Significance marking method: “ns” indicates no statistical difference (p ≥ 0.05); “*” indicates a significant difference (p < 0.05). Change rate = (after use - before use) / before use * 100%.

[0044] Figure 4 The graph shows the trend of changes in the average area of ​​crow's feet wrinkles. Compared with before product use, after 14 and 28 days of product use, the area of ​​crow's feet wrinkles decreased significantly (p < 0.05), decreasing by 9.37% and 17.51% respectively, indicating that the product has anti-wrinkle effects.

[0045] (3) Number of wrinkles Note: Significance marking method: “ns” indicates no statistical difference (p ≥ 0.05); “*” indicates a significant difference (p < 0.05). Change rate = (after use - before use) / before use * 100%.

[0046] Figure 5 The graph shows the trend of the average number of wrinkles in the test results. Compared with before using the product, after 14 days and 28 days of product use, the number of wrinkles decreased significantly (p<0.05) compared with the baseline value, decreasing by 13.25% and 18.82% respectively, indicating that the product has anti-wrinkle effects.

[0047] (4) Analysis of acceptance Based on the above test results, the following conclusions can be drawn: After continuous use of the product for 14 and 28 days, the 1% polypeptide complex stock solution prepared in Example 3 showed anti-wrinkle effects.

[0048] (5) Case studies of improved Visia images of the subjects are shown below. Figure 6 Image showing the area of ​​crow's feet wrinkles Figure 7 Image showing the effect of wrinkle count.

[0049] The preferred embodiments of the present invention disclosed above are merely illustrative of the invention. These preferred embodiments do not exhaustively describe all details, nor do they limit the invention to the specific implementations described. Clearly, many modifications and variations can be made based on the content of this specification. This specification selects and specifically describes these embodiments to better explain the principles and practical applications of the invention, thereby enabling those skilled in the art to better understand and utilize the invention.

Claims

1. A method for preparing a full-spectrum polypeptide complex, characterized in that, Includes the following steps: (1) Preparation of water-soluble polypeptide microspheres: Water-soluble polypeptides are mixed with carrier materials and water-soluble polypeptide microspheres are prepared by polysaccharide microsphere encapsulation technology. The polysaccharide microspheres are used to isolate the degradation of water-soluble polypeptides by proteases on the skin surface. (2) Preparation of lipid-soluble polypeptide liposomes: lipid-soluble polypeptides are mixed with carrier materials and lipid-soluble polypeptide liposomes are prepared by phospholipid liposome encapsulation technology. The structure of the phospholipid liposomes is similar to that of the lipids in the stratum corneum of the skin, which is used to promote the penetration of lipid-soluble polypeptides into the stratum corneum. (3) Complex mixing: The water-soluble polypeptide microspheres obtained in step (1) are mixed with the lipid-soluble polypeptide liposomes obtained in step (2), and stirred at 50°C to 58°C for 45 to 50 minutes to obtain a full-spectrum polypeptide complex intermediate. The full-spectrum polypeptide complex intermediate is composed of water-soluble polypeptides and lipid-soluble polypeptides, which act on the superficial layer of the skin and the dermis, respectively. (4) Formulation system construction: Add a basic solvent to the full-spectrum polypeptide complex intermediate, then add a composite preservative, and stir evenly; the basic solvent is a combination of butanediol and glycerol, with the butanediol addition ratio being 20% ​​to 25% and the glycerol addition ratio being 10% to 12%; the composite preservative is a combination of 1,2-hexanediol and pentanediol, with the 1,2-hexanediol addition ratio being 0.5% to 0.8% and the pentanediol addition ratio being 0.5% to 0.8%; (5) Finished product adjustment: Adjust the pH of the system to 5.0 to 6.0 with acid or alkali, add purified water, and prepare a full-spectrum polypeptide complex product with a concentration of 10% to 15%. The finished product is used for skin anti-wrinkle and repair.

2. The preparation method according to claim 1, characterized in that, The water-soluble polypeptide includes at least one of acetyl hexapeptide-8, acetyl octapeptide-3, acetyl hexapeptide-1, acetyl tetrapeptide-9, palmitoyl tetrapeptide-7, acetyl tetrapeptide-2, and tripeptide-1, and is used to construct the water-soluble component in the full-spectrum polypeptide system.

3. The preparation method according to claim 1, characterized in that, The lipid-soluble polypeptide includes at least one of palmitoyl pentapeptide-4, hexapeptide-11, snake venom-like peptide, palmitoyl tripeptide-1, and palmitoyl tripeptide-5, and is used to construct the lipid-soluble component in the full-spectrum polypeptide system.

4. The preparation method according to claim 1, characterized in that, In step (1), the carrier material for the water-soluble polypeptide microspheres is one of polyethylene glycol, polyvinylpyrrolidone, and polyvinyl alcohol. The carrier material is adapted to the water-soluble polypeptide to achieve slow release. In step (2), the carrier material for the lipid-soluble polypeptide liposomes is one of polyethylene glycol octyl ether, polyglycerol ester, and polyvinyl alcohol octyl ester. The carrier material is adapted to the lipid-soluble polypeptide to improve the penetration efficiency of the stratum corneum.

5. The preparation method according to claim 1, characterized in that, The acid used to adjust the pH value in step (5) is hydrochloric acid, and the base used is sodium hydroxide.

6. The preparation method according to claim 1, characterized in that, In step (1), the mass ratio of water-soluble peptides to carrier materials is 1:(5-10).

7. The preparation method according to claim 1, characterized in that, In step (2), the mass ratio of the lipid-soluble peptide to the carrier material is 1:(5-10).

8. The preparation method according to claim 1, characterized in that, In step (3), the mass ratio of water-soluble polypeptide microspheres to lipid-soluble polypeptide liposomes is (1-2):

1.

9. The preparation method according to claim 1, characterized in that, In step (4), the stirring speed is 200 rpm to 300 rpm and the stirring time is 20 minutes to 30 minutes.

10. A full-spectrum polypeptide complex, characterized in that, Prepared using any one of the preparation methods described in claims 1 to 9, the complex comprises a dual-targeting structure of water-soluble polypeptide microspheres and lipid-soluble polypeptide liposomes, and the full spectrum of polypeptides covers both water-soluble and lipid-soluble types.

Images